Hepatic dysfunction in children with tuberculosis on treatment with antituberculous therapy
Journal Title: Annals of Hepatology - Year 2012, Vol 11, Issue 1
Abstract
Aim. To determine the incidence and factors associated with drug induced hepatic dysfunction in children on anti-tuberculous treatment (ATT). Setting. Pediatric Tuberculosis Clinic at B.J. Wadia Children’s Hospital, Mumbai. Material and methods. 46 children with tuberculosis on ATT between April 2007 and February 2008 were included. Serum glutamic pyruvic transaminase (SGPT) level was measured at the beginning, after 15 days of starting ATT, at the end intensive phase and then if the patient developed symptoms of hepatic dysfunction. A value 3 times the normal value of the testing laboratory was considered to be significant for liver dysfunction. Liver dysfunction was analysed for association with factors like age, sex, weight, malnutrition, type of tuberculosis and severity of tuberculosis using SPSS Statistics software, Version 15.0. Results. Seven (15.2 %) out of 46 children developed drug induced hepatic dysfunction, of which 2 (28.6%) patients had 2 episodes of liver dysfunction while 5 (71.4%) had 1 episode of liver dysfunction. One (14.3%) developed symptom of hepatitis in the form of jaundice and hepatomegaly. All the patients developing liver dysfunction were in the intensive phase of treatment. The mean age of the children developing liver dysfunction was 4.0 ± 3.76 years. Liver dysfunction was associated with age younger than 3½ years (p = 0.025). Liver dysfunction was not associated with sex, weight, malnutrition, type of tuberculosis and severity of tuberculosis. Conclusion. Regular monitoring of SGPT levels is recommended in all children on ATT below the age of 3 ½ years.
Authors and Affiliations
Sasha Mansukhani, Ira Shah
Keywords
Related Articles
- EP ID EP78105
- DOI -
- Views 118
- Downloads 0
Prevalence of hepatitis B seropositivity among Thai workers in screening program before going abroad.
Visceral adipose tissue visfatin in nonalcoholic fatty liver disease
Background. Visfatin is a novel adipocytokine predominantly expressed and secreted by visceral adipose tissue. It is realized for its multiple functions of central importance in NAD biosynthesis, innate immunity and infl...
Acute and fulminant hepatitis induced by flutamide: Case series report and review of the literature
Flutamide is a non-steroidal anti-androgenic drug, commonly used in the treatment of advanced prostate cancer, acne and hirsutism. This drug may induce various degrees of liver injury, including acute liver failure (ALF)...
Nonalcoholic fatty liver disease and polycystic ovary syndrome
Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP)
Therapies for immune thrombocytopenia (ITP) may be associated with abnormal hepatobiliary laboratory (HBL) values, but the epidemiology of these abnormalities is unknown in the ITP population. The study aim was to provid...